Effect of dapagliflozin on the structural and functional properties of arterial vessels in patients with type 2 diabetes mellitus in combination with obesity
DOI:
https://doi.org/10.14739/2310-1237.2020.3.221734Keywords:
type 2 diabetes mellitus, owerweight, obesity, arterial stiffness, dapagliflozinAbstract
Modern trends in the treatment of type 2 diabetes mellitus (DM) should include not only the normalization of carbohydrate metabolism disorders, but also a possible positive effect on the cardiovascular system. The use of the drug dapagliflozin for several years has proven to reduce the manifestations of heart failure. However, the possible significance of dapagliflozin in the reversal of structural and functional changes in the arteries in patients with type 2 DM and obesity has not been studied enough.
The aim of the study was to establish the possibility of correction of structural and functional disorders of arterial vessels in patients with type 2 DM in combination with excess body weight (EBW) and obesity with dapagliflozin as part of complex therapy.
Material and methods. 99 people were examined, including 71 patients with diabetes mellitus, the DM (type 2) diagnosis was verified according to the primary documentation. All patients provided written informed consent to participate in the study. Among the patients, the first group consisted of 36 people (14 women and 22 men) with EBW and obesity (body mass index >25), average age 55.91 ± 1.58 years, the duration of DM was on average 8.55 ± 0.65 years (with a range from the first identified to 18 years). The second group consisted of 35 people (11 women and 24 men with normal body weight (body mass index ≤25), the average age was 56.91 ± 1.95 years, the duration of DM was on average 5.73 ± 1.02 years (with a range from the first identified to 22 years). As a control, a group of 28 practically healthy individuals was examined, which was comparable to the first and second groups in terms of gender (11 women, 17 men) and age (56.05 ± 1.88 years old).
Dapagliflozin was prescribed to the examined persons of the 1st group in a daily dose of 10 mg as an antidiabetic agent as part of complex therapy. All examinations were carried out before the start of dapagliflozin treatment, as well as after 12 weeks of therapy.
Results. Patients with type 2 DM and EBW showed the highest level of expression of caspase-3, TGF-β1 and an increase in arterial stiffness in elastic and muscular vessels compared to patients with type 2 DM without EBW, and especially compared to the control group.
During treatment with dapagliflozin as part of complex therapy, a significant decrease in the TGF-β1 index, caspase-3 expression and a decrease in the speed of pulse wave propagation through the muscular and elastic arteries on the upper and lower extremities were recorded in patients with type 2 DM in combination with EBW and obesity.
Conclusions. Dapagliflozin therapy, in addition to reliable inhibition of fibrosis processes and mechanisms of apoptosis activation in diabetes, also statistically significantly improves the arterial wall stiffness of both elastic and muscular vessels, reducing the progression of vasculopathies. In individuals with increased expression markers of fibrosis TGF-β1, significantly more rigid vessels of the elastic and muscular type are determined, which indicates a possible pathogenetic role of TGF-β1 as one of the potential prognostic biomarkers of arterial stiffness and a negative factor of cardiovascular risk in patients with type 2 DM in combination with EBW.
References
Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019). Understanding the mechanisms of reversal of type 2 diabetes. The lancet. Diabetes & endocrinology, 7(9), 726-736. https://doi.org/10.1016/S2213-8587(19)30076-2
Perng, W., Oken, E., & Dabelea, D. (2019). Developmental overnutrition and obesity and type 2 diabetes in offspring. Diabetologia, 62(10), 1779-1788. https://doi.org/10.1007/s00125-019-4914-1
McMurray, J., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., & DAPA-HF Committees and Investigators (2019). The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European journal of heart failure, 21(11), 1402-1411. https://doi.org/10.1002/ejhf.1548
Pan, F. S., Xu, M., Yu, L., Luo, J., Li, M. Y., Liang, J. Y., Zheng, Y. L., & Xie, X. Y. (2019). Relationship between carotid intima-media thickness and carotid artery stiffness assessed by ultrafast ultrasound imaging in patients with type 2 diabetes. European journal of radiology, 111, 34-40. https://doi.org/10.1016/j.ejrad.2018.12.016
Chang, A. S., Hathaway, C. K., Smithies, O., & Kakoki, M. (2016). Transforming growth factor-β1 and diabetic nephropathy. American journal of physiology. Renal physiology, 310(8), F689-F696. https://doi.org/10.1152/ajprenal.00502.2015
Shibusawa, R., Yamada, E., Okada, S., Nakajima, Y., Bastie, C. C., Maeshima, A., Kaira, K., & Yamada, M. (2019). Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Scientific reports, 9(1), 9887. https://doi.org/10.1038/s41598-019-46402-6
Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., … Kosiborod, M. (2019). Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation, 140(18), 1463-1476. https://doi.org/10.1161/CIRCULATIONAHA.119.042929
Avgerinos, I., Liakos, A., Tsapas, A., & Bekiari, E. (2019). Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes, metabolic syndrome and obesity : targets and therapy, 12, 2549-2557. https://doi.org/10.2147/DMSO.S190356
Papakitsou, I., Vougiouklakis, G., Elisaf, M. S., & Filippatos, T. D. (2019). Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical pharmacology : advances and applications, 11, 133-143. https://doi.org/10.2147/CPAA.S172353
Tromp, J., & Collins, S. P. (2019). Dapagliflozin in heart failure: new frontiers. European journal of heart failure, 21(11), 1412-1414. https://doi.org/10.1002/ejhf.1633
Park, S. H., Farooq, M. A., Gaertner, S., Bruckert, C., Qureshi, A. W., Lee, H. H., Benrahla, D., Pollet, B., Stephan, D., Ohlmann, P., Lessinger, J. M., Mayoux, E., Auger, C., Morel, O., & Schini-Kerth, V. B. (2020). Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovascular diabetology, 19(1), 19. https://doi.org/10.1186/s12933-020-00997-7
Giraldo-Grueso, M., & Echeverri, D. (2020). From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus. Current diabetes reviews, 16(3), 230-237. https://doi.org/10.2174/1573399814666181017120415
Eleftheriadis, T., Pissas, G., Tsogka, K., Nikolaou, E., Liakopoulos, V., & Stefanidis, I. (2020). A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin. International urology and nephrology, 52(6), 1179-1189. https://doi.org/10.1007/s11255-020-02481-3
Hussein, A. M., Eid, E. A., Taha, M., Elshazli, R. M., Bedir, R. F., & Lashin, L. S. (2020). Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms. Biomedicines, 8(3), 43. https://doi.org/10.3390/biomedicines8030043
Wang, S. Q., Li, D., & Yuan, Y. (2019). Long-term moderate intensity exercise alleviates myocardial fibrosis in type 2 diabetic rats via inhibitions of oxidative stress and TGF-β1/Smad pathway. The journal of physiological sciences : JPS, 69(6), 861-873. https://doi.org/10.1007/s12576-019-00696-3
Jia, Y., Reddy, M. A., Das, S., Oh, H. J., Abdollahi, M., Yuan, H., Zhang, E., Lanting, L., Wang, M., & Natarajan, R. (2019). Dysregulation of histone H3 lysine 27 trimethylation in transforming growth factor-β1-induced gene expression in mesangial cells and diabetic kidney. The Journal of biological chemistry, 294(34), 12695-12707. https://doi.org/10.1074/jbc.RA119.007575
Smina, T. P., Rabeka, M., & Viswanathan, V. (2019). Diabetic Foot Ulcer as a Cause of Significant Decline in the Renal Function Among South Indian Population With Type 2 Diabetes: Role of TGF-β1 and CCN Family Proteins. The international journal of lower extremity wounds, 18(4), 354-361. https://doi.org/10.1177/1534734619862704
Zhang, N., Feng, B., Ma, X., Sun, K., Xu, G., & Zhou, Y. (2019). Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular diabetology, 18(1), 107. https://doi.org/10.1186/s12933-019-0914-1
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
